Immune globulin infusion (human), 10% with recombinant human hyaluronidase - Biologic Drug Details

Summary for immune globulin infusion (human), 10% with recombinant human hyaluronidase

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for immune globulin infusion (human), 10% with recombinant human hyaluronidase

Recent Clinical Trials for immune globulin infusion (human), 10% with recombinant human hyaluronidase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Baxalta now part of Shire	Phase 1
Baxalta Innovations GmbH, now part of Shire	Phase 1

See all immune globulin infusion (human), 10% with recombinant human hyaluronidase clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin infusion (human), 10% with recombinant human hyaluronidase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin infusion (human), 10% with recombinant human hyaluronidase Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	HYQVIA	immune globulin infusion (human), 10% with recombinant human hyaluronidase	Injection	125402		2024-03-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for immune globulin infusion (human), 10% with recombinant human hyaluronidase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for immune globulin infusion (human), 10% with recombinant human hyaluronidase

Country	Patent Number	Estimated Expiration
European Patent Office	2311973
South Korea	101363658
Spain	2557818
South Korea	101363823

Supplementary Protection Certificates for immune globulin infusion (human), 10% with recombinant human hyaluronidase

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
92780	Luxembourg		PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
122015000061	Germany		PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
300822	Netherlands		PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 20140326
C02405015/01	Switzerland		PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016

Market Dynamics and Financial Trajectory for Human Immunoglobulin Infusion (10%) with Recombinant Human Hyaluronidase

Last updated: March 1, 2026

What Are the Key Market Drivers?

The biologic drug, comprising human immunoglobulin G (IVIG) at 10% concentration combined with recombinant human hyaluronidase (hialuronidase), targets immunodeficiency, autoimmune diseases, and certain neurological conditions. The market is shaped by the following primary drivers:

• Growing Prevalence of Immunodeficiency Disorders: Primary immunodeficiency (PID) affects an estimated 1 in 2,000 to 2,500 individuals globally, increasing demand for IVIG therapies [1].

• Increasing Autoimmune Disease Incidence: Conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP) and Guillain-Barré syndrome (GBS) contribute substantially to IVIG utilization. CIDP affects approximately 1-2 per 100,000 people annually [2].

• Advantages of Recombinant Hyaluronidase: Enhances subcutaneous absorption of IVIG, reduces infusion times, and improves patient compliance, particularly in outpatient settings.

• Regulatory Approvals and Expanding Indications: Approval of new formulations and expanded indications propel market growth.

• Emerging Biosimilar and Biobetter Competition: Entry of biosimilars exerts downward pressure on prices but expands overall market size.

• Pricing and Reimbursement Policies: Variations across regions influence market penetration and profitability.

What Is the Current Market Size and Growth?

The global market for IVIG therapies, including formulations with recombinant hyaluronidase, was valued at approximately USD 9.2 billion in 2022 [3].

Market Breakdown:

Region	Market Share (2022)	Key Growth Factors
North America	45%	High prevalence, established healthcare systems
Europe	25%	Aging population, expanding indications
Asia-Pacific	15%	Rising awareness, developing healthcare markets
Rest of World	15%	Limited access, growing demand

Compound Annual Growth Rate (CAGR):

The overall IVIG market, including those with recombinant hyaluronidase, reports a CAGR of approximately 8-10% from 2023 to 2028 [3].

How Do Product Features Influence Market Share?

The 10% human immunoglobulin dose with recombinant hyaluronidase offers several advantages that influence market positioning:

• Higher Concentration (10%): Allows for smaller infusion volumes, reducing patient discomfort and infusion time.

• Recombinant Human Hyaluronidase: Facilitates subcutaneous administration with broader patient applicability, especially for those unable to tolerate intravenous routes.

• Improved Convenience: Shorter infusion times and less frequent dosing improve patient adherence and reduce healthcare resource utilization.

• Safety Profile: Superior or comparable safety compared to standard IVIG formulations fosters physician confidence.

What Are the Key Competitive Dynamics?

Major players developing or marketing drugs in this segment include:

• Octapharma AG: Markets Hizentra, a 20% subcutaneous immunoglobulin with recombinant hyaluronidase (sold as HyQvia in some regions).

• Grifols SA: Markets Privigen, with ongoing development of hyaluronidase-based formulations.

• CSL Behring: Offers Privigen and has research into enhanced formulations.

The market exhibits a trend toward developing biobetter formulations with higher concentrations and optimized infusion profiles.

What Is the Financial Outlook?

Revenue Projections:

• The global IVIG market is projected to reach USD 15.5–16.2 billion by 2028, reflecting the 8-10% CAGR [3].

• The segment containing recombinant hyaluronidase-based formulations is expected to grow faster, at approximately 12%, driven by advantages in ease of administration.

Pricing Dynamics:

• Average IVIG therapy costs range from USD 10,000 to USD 20,000 per year per patient in North America; hyaluronidase-enabled products may command premiums up to 15-20% because of improved convenience.

• Price erosion due to biosimilar entry is projected at 4-6% annually, which affects revenue trajectories but may expand market size due to increased accessibility.

Cost Considerations:

• Manufacturing costs are rising, owing to the complexity of biologic production and quality control standards.

• The recombinant hyaluronidase component adds to R&D expenses but supports premium pricing.

What Are the Regulatory and Policy Impact Factors?

• FDA and EMA: Approve formulations with recombinant hyaluronidase based on safety and efficacy data. Ongoing post-market surveillance influences acceptance.

• Regional reimbursement policies: Influence adoption rates. Higher reimbursement correlates with broader use of hyaluronidase-based products.

• Intellectual Property: Patents covering recombinant hyaluronidase and specific formulations protect market share until expiration, typically around 2030-2035.

What Risks Could Impact Market Trajectory?

• Biologic Price Competition: Entry of biosimilars could reduce prices and margins.

• Supply Chain Disruptions: Dependence on complex biologic manufacturing exposes the market to raw material shortages or contamination risks.

• Emergence of Alternative Therapies: New immunomodulatory drugs could replace IVIG in some indications.

• Regulatory Barriers: Stringent approval processes or restrictions may delay product launches.

Key Takeaways

• The global IVIG and recombinant hyaluronidase segment is mature but expanding driven by increased demand and innovation.

• The 10% human immunoglobulin with recombinant hyaluronidase offers clinical advantages that support premium pricing and market share growth.

• Revenue growth is forecasted at a 8-10% CAGR for the IVIG market overall, with hyaluronidase-enabled formulations growing faster at near 12%.

• Regional variations, reimbursement policies, and patent protections significantly influence revenues.

• The competitive landscape emphasizes innovation, with biosimilar entry and biobetter development being key factors.

FAQs

1. What are the main clinical advantages of recombinant hyaluronidase in immunoglobulin therapies?
   It allows subcutaneous administration with faster infusion times, increased absorption, and improved patient convenience.

2. How is the market share split among key players?
   Major companies such as Octapharma, Grifols, and CSL Behring hold significant portions, with market shares around 20-40% each, depending on the region and product portfolio.

3. What are the primary indications for this formulation?
   Immunodeficiency syndromes, autoimmune diseases like CIDP, neurological conditions, and off-label uses for other immune-modulating therapies.

4. What is the impact of biosimilars on this market?
   Biosimilars could lower prices and challenge established brands; however, they also expand overall market size by increasing access.

5. When will the patent protections for current recombinant hyaluronidase formulations expire?
   Patent expiry is expected around 2030–2035, opening opportunities for biosimilar development.

---

References

[1] Orange, J. S., et al. (2020). Patient age and serum IgG levels as determinants of immune deficiency severity. Journal of Clinical Immunology, 40(5), 555–569.

[2] Van den Berg, L. H., et al. (2010). Chronic inflammatory demyelinating polyneuropathy: clinical features, diagnosis, and management. The Lancet Neurology, 9(2), 192–202.

[3] MarketsandMarkets. (2022). Intravenous Immunoglobulin Market by Product Type, Indication, and Region. Retrieved from https://www.marketsandmarkets.com